TB-500 Research: Mechanism, Models & Sourcing

What is TB-500?

TB-500 is the name commonly used in the research-chemical literature for a synthetic peptide corresponding to the actin-binding region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide present in many mammalian cell types. Tβ4 is described in the literature as one of the principal intracellular G-actin sequestering molecules. The fragment marketed as TB-500 is frequently associated with the conserved LKKTET / LKKTETQ actin-binding motif that researchers have studied in connection with Tβ4 activity.

Within VANTA's catalog, TB-500 is supplied strictly as a reference material for in-vitro and laboratory research. It is not a dietary supplement, drug, or medical product, and nothing here should be read as a claim about safety or effect in humans or animals.

Studied mechanisms in the literature

The most extensively characterized property of thymosin beta-4 in published work is its binding to monomeric globular actin (G-actin). Researchers have reported that Tβ4 forms a roughly 1:1 complex with G-actin and, in these models, is associated with shifting the G-actin/F-actin equilibrium and modulating cytoskeletal dynamics (PMID 23811404).

Beyond actin sequestration, the conserved actin-binding site has itself been examined in relation to angiogenic readouts in experimental systems (PMID 14500546). Review literature has further catalogued proposed modes of action, including effects observed on cell migration and endothelial behavior in preclinical and in-vitro settings (PMID 17632766). These descriptions reflect findings reported by investigators and are presented here only as a summary of the published record.

Research models and reported findings (hedged)

TB-500 / thymosin beta-4 appears across several distinct preclinical research areas. In dermal and cutaneous studies, animal-model work has examined associations with re-epithelialization, collagen deposition, and angiogenesis at wound sites (PMID 15037013; PMID 27450738). Investigators have used rodent full-thickness wound and diabetic-model systems to characterize these readouts.

A separate body of cardiovascular literature has investigated Tβ4 in the context of coronary vessel development and epicardial activation in animal models (PMID 17495252). Across these reports, outcomes are described in terms of cellular and tissue-level observations in laboratory systems.

These studies are referenced to characterize where the molecule has been examined by researchers. They do not establish efficacy, are not therapeutic conclusions, and have no bearing on human use.

Why researchers care about identity and purity

Because peptide research outcomes can be confounded by sequence errors, truncation products, residual synthesis reagents, and counterion or salt content, the analytical identity of a reference peptide is central to reproducible work. For a molecule like TB-500, where conclusions in the literature depend on the integrity of a specific actin-associated sequence, an impure or misidentified sample can quietly undermine an experiment.

This is why reference-grade suppliers treat per-lot analytical documentation as a baseline expectation rather than an add-on. Researchers evaluating a source typically look for both a confirmed mass/identity and a quantified purity figure tied to the exact lot in hand.

How VANTA verifies it

VANTA treats every TB-500 lot as something to be measured, not assumed. Identity is confirmed by mass spectrometry, which checks the observed molecular mass of the peptide against the expected theoretical mass for the sequence. Purity is assessed by reverse-phase high-performance liquid chromatography (HPLC), which resolves the main peak from related impurities and truncation or deletion products and reports a percentage purity.

Each batch ships with a per-batch Certificate of Analysis (COA) documenting the HPLC purity result and the mass-spec identity confirmation for that specific lot. This per-lot approach lets researchers tie the material in front of them to its own analytical record rather than to a generic specification, supporting traceable, reproducible laboratory work.

Compliance and intended use

All VANTA materials, including TB-500, are sold exclusively for laboratory and in-vitro research use by qualified professionals. They are not intended for human or veterinary use, ingestion, injection, or any form of consumption, and are not drugs, foods, cosmetics, or medical devices.

Nothing on this page is medical advice or a claim that TB-500 treats, prevents, or improves any condition. References to published studies describe work conducted in laboratory and animal models only. Researchers are responsible for handling, storing, and using reference materials in accordance with applicable institutional and regulatory requirements.